Immatics NV reports results for the quarter ended March 31 - Earnings Summary

• Immatics NV IMTX reported a quarterly adjusted loss of 33 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -3 cents. The mean expectation of four analysts for the quarter was for a loss of 32 cents per share. Wall Street expected results to range from -36 cents to -24 cents per share.

• Revenue fell 38.6% to €18.58 million from a year ago; analysts expected €13.96 million.

• Immatics NV's reported EPS for the quarter was a loss of 33 cents​.

• The company reported a quarterly loss of €39.86 million.

• Immatics NV shares had risen by 1.1% this quarter and lost 35.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 54.8% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy"

• Wall Street's median 12-month price target for Immatics NV is $15.50

This summary was machine generated from LSEG data May 13 at 12:43 p.m. UTC. ​All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)